Expressive

rs117767021 - LINC02843 - MIR4289

Magnitude 4.5 · 1 study on file

Reported associations

  • Sulfasalazine‐Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus - Unknown journal (n.d.) · Unknown authors · PubMed 28762467

    ABSTRACT: Agranulocytosis is a serious, although rare, adverse reaction to sulfasalazine, which is used to treat inflammatory joint and bowel disease. We performed a genome‐wide association study comprising 9,380,034 polymorphisms and 180 HLA alleles in 36 cases of sulfasalazine‐induced agranulocytosis and 5,170 population controls. Sulfasalazine‐induced agranulocytosis was significantly associated with the HLA region on chromosome 6. The top hit (rs9266634) was located close to HLA‐B, odds ratio (OR) 5.36 (95% confidence interval (CI) (2.97, 9.69) P = 2.55 × 10−8). We HLA‐sequenced a second cohort consisting of 40 cases and 142 treated controls, and confirmed significant associations with HLA‐B*08:01, OR = 2.25 (95% CI (1.02, 4.97) P = 0.0439), in particular the

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Bloodwork

  • white blood cell count if sulfasalazine must be used Moderate

    sulfasalazine-induced agranulocytosis risk is highest during initial treatment period

    baseline CBC before starting, weekly for first month, then monthly

Discuss with your doctor

  • sulfasalazine-induced agranulocytosis risk with prescriber Moderate

    rs117767021 variant status increases sulfasalazine safety risk

    mention genetic variant before drug initiation

Drug interactions

  • sulfasalazine alternatives due to agranulocytosis risk Moderate

    rs117767021 variant carriers have 10.78-fold increased risk of agranulocytosis with sulfasalazine exposure